Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...

Pharmaceuticals announced that 23 abstracts, including six oral presentations, showcasing compelling Revuforj and Niktimvo data were accepted for presentation at the 67th American Society of ...